Martha Arellano MD

Department of Hematology and Medical Oncology
Professor

marella@emory.edu

Overview

Board certified in hematology, medical oncology and internal medicine, Dr. Arellano specializes in the treatment of leukemia and myelodysplastic syndromes. She started practicing with Emory Healthcare in 2006.

Dr. Arellano is a clinical member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University. She currently leads the Department of Hematology and Medical Oncology's Fellowship program.

Dr. Arellano earned her medical degree from Emory University School of Medicine in Atlanta, Georgia. She went on to complete her internship and residency at Emory University Hospital in Atlanta, Georgia.

Dr. Arellano's primary research focus is in the development of novel therapies for older adults with acute leukemias and myelodysplastic syndromes and immune-based therapies for hematological malignancies.

She is principal investigator on therapeutic trials for patients with acute leukemias and myelodysplastic syndromes, including immunotherapy and allogeneic transplantation. She is also co-investigator on a tissue repository for hematological disorders, a project that leads to collaborations with scientists within and outside of Emory University.

Dr. Arellano has published in a number of leading journals including Journal of Clinical Oncology, Biology of Blood and Marrow Transplantation and Leukemia and Lymphoma.

Dr. Arellano received the 2018 James R. Eckman Award for Teaching Excellence from the Emory Department of Hematology and Medical Oncology Fellowship Program.

Academic Appointment

Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Education

Degrees

MD from Emory University School of Medicine
Bachelor Degree from Georgia State University

Research

Focus

Novel therapies for older adults with acute leukemias and myelodysplastic syndromes; immune-based therapies for hematological malignancies.

Publications

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.
Blood
05/07/2025 Authors: Arellano ML; Thirman MJ; DiPersio JF; Heiblig M; Stein EM; Schuh AC; Zucenka A; De Botton S; Grove CS; Mannis GN
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Leukemia Volume: 39 Page(s): 1058 - 1068
05/01/2025 Authors: Shah BD; Cassaday RD; Park JH; Houot R; Logan AC; Boissel N; Leguay T; Bishop MR; Topp MS; O'Dwyer KM
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial.
Blood Cancer J Volume: 15 Page(s): 55
04/03/2025 Authors: Hoff FW; Huang Y; Welkie RL; Swords RT; Traer E; Stein EM; Lin TL; Patel PA; Collins RH; Baer MR
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia.
Blood Cancer J Volume: 15 Page(s): 49
03/28/2025 Authors: Pullarkat V; Pratz KW; Dhner H; Recher C; Thirman MJ; DiNardo CD; Fenaux P; Schuh AC; Wei AH; Pigneux A
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
J Clin Oncol Volume: 43 Page(s): 75 - 84
01/01/2025 Authors: Issa GC; Aldoss I; Thirman MJ; DiPersio J; Arellano M; Blachly JS; Mannis GN; Perl A; Dickens DS; McMahon CM
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.
N Engl J Med Volume: 391 Page(s): 2219 - 2230
12/12/2024 Authors: Roddie C; Sandhu KS; Tholouli E; Logan AC; Shaughnessy P; Barba P; Ghobadi A; Guerreiro M; Yallop D; Abedi M
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
Blood Adv Volume: 8 Page(s): 5297 - 5305
10/22/2024 Authors: Hoff FW; Blum WG; Huang Y; Welkie RL; Swords RT; Traer E; Stein EM; Lin TL; Archer KJ; Patel PA
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
Blood Adv Volume: 8 Page(s): 4209 - 4220
08/13/2024 Authors: DiNardo CD; Roboz GJ; Watts JM; Madanat YF; Prince GT; Baratam P; de Botton S; Stein A; Foran JM; Arellano ML
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
Target Oncol Volume: 19 Page(s): 321 - 332
05/01/2024 Authors: Maris M; Salles G; Kim WS; Kim TM; Lyons RM; Arellano M; Karmali R; Schiller G; Cull E; Abboud CN
Ivosidenib in Mutant IDH1 Relapsed/ Refractory Myelodysplastic Syndrome: Updated Substudy Results
Volume: 23 Page(s): S366 - S367
09/01/2023 Authors: DiNardo CD; Roboz GJ; Watts JM; Madanat YF; Prince GT; Baratam P; de Botton S; Stein A; Foran JM; Arellano ML
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
J Immunother Cancer Volume: 11
08/01/2023 Authors: Shah BD; Cassaday RD; Park JH; Houot R; Oluwole OO; Logan AC; Boissel N; Leguay T; Bishop MR; Topp MS
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Cancer Volume: 129 Page(s): 2308 - 2320
08/01/2023 Authors: Duong VH; Ruppert AS; Mims AS; Borate U; Stein EM; Baer MR; Stock W; Kovacsovics T; Blum W; Arellano ML
Passenger pathogens on physicians.
Am J Infect Control Volume: 51 Page(s): 807 - 811
07/01/2023 Authors: Funk CR; Ravindranathan S; Matelski A; Zhang H; Taylor C; Chandrasekaran S; Arellano M; Langston AA; Joseph N; Waller EK
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
Blood Adv Volume: 7 Page(s): 2360 - 2363
06/13/2023 Authors: Saliba AN; Kaufmann SH; Stein EM; Patel PA; Baer MR; Stock W; Deininger M; Blum W; Schiller GJ; Olin RL
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Nature Volume: 615 Page(s): 920 - 924
03/01/2023 Authors: Issa GC; Aldoss I; DiPersio J; Cuglievan B; Stone R; Arellano M; Thirman MJ; Patel MR; Dickens DS; Shenoy S
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.
J Hematol Oncol Volume: 15 Page(s): 170
12/10/2022 Authors: Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D
Impact of Venetoclax and Azacitidine in Treatment-Nave Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.
Clin Cancer Res Volume: 28 Page(s): 2753 - 2761
07/01/2022 Authors: Pollyea DA; DiNardo CD; Arellano ML; Pigneux A; Fiedler W; Konopleva M; Rizzieri DA; Smith BD; Shinagawa A; Lemoli RM
Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Therapy-related Myeloid Neoplasms, Antecedent Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Volume: 197 Page(s): 58 - 59
04/01/2022 Authors: Pullarkat V; Pratz KW; Doehner H; Recher C; Thirman MJ; DiNardo CD; Fenaux P; Schuh AC; Wei AH; Pigneux A
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
Cancer Volume: 127 Page(s): 4421 - 4431
12/01/2021 Authors: Kantarjian HM; Begna KH; Altman JK; Goldberg SL; Sekeres MA; Strickland SA; Arellano ML; Claxton DF; Baer MR; Gautier M
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
Mol Cell Volume: 81 Page(s): 3833 - 3847.e11
09/30/2021 Authors: Chen D; Xia S; Zhang R; Li Y; Famulare CA; Fan H; Wu R; Wang M; Zhu AC; Elf SE
Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)
Volume: 44 Page(s): 16 - 16
09/01/2021 Authors: Topp MS; Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Forcade E; Bishop MR; Tzachanis D
Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study
Volume: 21 Page(s): S346 - S347
09/01/2021 Authors: DiNardo CD; Foran JM; Watts JM; Stein EM; de Botton S; Fathi AT; Prince GT; Stein AS; Stone RM; Patel PA
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
Lancet Volume: 398 Page(s): 491 - 502
08/07/2021 Authors: Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
Blood Volume: 138 Page(s): 11 - 22
07/08/2021 Authors: Shah BD; Bishop MR; Oluwole OO; Logan AC; Baer MR; Donnellan WB; O'Dwyer KM; Holmes H; Arellano ML; Ghobadi A
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia.
JCO Oncol Pract Volume: 17 Page(s): e497 - e505
04/01/2021 Authors: Jillella AP; Arellano ML; Gaddh M; Langston AA; Heffner LT; Winton EF; McLemore ML; Zhang C; Caprara CR; Simon KS
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
Blood Volume: 137 Page(s): 751 - 762
02/11/2021 Authors: Uy GL; Aldoss I; Foster MC; Sayre PH; Wieduwilt MJ; Advani AS; Godwin JE; Arellano ML; Sweet KL; Emadi A
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
Am J Hematol Volume: 96 Page(s): 208 - 217
02/01/2021 Authors: Pollyea DA; Pratz K; Letai A; Jonas BA; Wei AH; Pullarkat V; Konopleva M; Thirman MJ; Arellano M; Becker PS
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
Nat Med Volume: 26 Page(s): 1852 - 1858
12/01/2020 Authors: Burd A; Levine RL; Ruppert AS; Mims AS; Borate U; Stein EM; Patel P; Baer MR; Stock W; Deininger M
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.
Blood Adv Volume: 4 Page(s): 5011 - 5024
10/27/2020 Authors: Vadakekolathu J; Lai C; Reeder S; Church SE; Hood T; Lourdusamy A; Rettig MP; Aldoss I; Advani AS; Godwin J
Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors.
J Clin Med Volume: 9
05/20/2020 Authors: Kong JH; Winton EF; Heffner LT; Gaddh M; Hill B; Neely J; Hatcher A; Joseph M; Arellano M; El-Rassi F
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia.
Blood Adv Volume: 4 Page(s): 983 - 992
03/24/2020 Authors: Lee CJ; Kim S; Tecca HR; Bo-Subait S; Phelan R; Brazauskas R; Buchbinder D; Hamilton BK; Battiwalla M; Majhail NS
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood Volume: 135 Page(s): 463 - 471
02/13/2020 Authors: Roboz GJ; DiNardo CD; Stein EM; de Botton S; Mims AS; Prince GT; Altman JK; Arellano ML; Donnellan W; Erba HP
ERRATUM: Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation.
Hematol Rep Volume: 11 Page(s): 8395
11/29/2019 Authors: Jillella AP; Arellano ML; Heffner LT; Gaddh M; Langston AA; Khoury HJ; Mangaonkar A; Kota VK
Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart (R) Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
Volume: 134
11/13/2019 Authors: Uy GL; Aldoss I; Foster MC; Sallman DA; Sweet KL; Rizzieri DA; Sayre PH; Advani AS; Emadi A; Wieduwilt MJ
Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly- Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study
Volume: 19 Page(s): S220 - S220
09/01/2019 Authors: DiNardo CD; Roboz GJ; Stein EM; de Botton S; Mims AS; Prince GT; Altman JK; Arellano ML; Donnellan W; Erba HP
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.
Cancer Discov Volume: 9 Page(s): 756 - 777
06/01/2019 Authors: Chen D; Xia S; Wang M; Lin R; Li Y; Mao H; Aguiar M; Famulare CA; Shih AH; Brennan CW
Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study.
Volume: 37
05/20/2019 Authors: Roboz GJ; Dinardo CD; Stein EM; de Botton S; Mims AS; Prince GT; Altman JK; Arellano ML; Erba HP; Pollyea DA
Updated Phase 1 Results of Zuma-3: Kte-X19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Volume: 25
03/01/2019 Authors: GWierda W; Bishop MR; Oluwole O; Logan AC; Baer MR; Donnellan WB; O'Dwyer KM; Castro JE; Schiller GJ; Holmes H
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.
Blood Adv Volume: 3 Page(s): 508 - 518
02/26/2019 Authors: Garcia-Manero G; Abaza Y; Takahashi K; Medeiros BC; Arellano M; Khaled SK; Patnaik M; Odenike O; Sayar H; Tummala M
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Blood Volume: 133 Page(s): 7 - 17
01/03/2019 Authors: DiNardo CD; Pratz K; Pullarkat V; Jonas BA; Arellano M; Becker PS; Frankfurt O; Konopleva M; Wei AH; Kantarjian HM
Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Volume: 132
11/29/2018 Authors: Wierda WG; Bishop MR; Oluwole OO; Logan AC; Baer MR; Donnellan WB; O'Dwyer KM; Castro JE; Schiller GJ; Holmes H
Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart (R) Molecule for T-Cell Redirected Therapy
Volume: 132
11/29/2018 Authors: Jacobs K; Viero C; Godwin J; Baughman J; Sun J; Ying K; Muth J; Hong S; Vey N; Sweet KL
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
Am J Hematol Volume: 93 Page(s): 1301 - 1310
11/01/2018 Authors: Cortes JE; Douglas Smith B; Wang ES; Merchant A; Oehler VG; Arellano M; DeAngelo DJ; Pollyea DA; Sekeres MA; Robak T
TREATMENT OF VENOUS THROMBOEMBOLISM DURING INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE LEUKEMIA: A SINGLE CENTER EXPERIENCE
Volume: 93 Page(s): E51 - E51
09/01/2018 Authors: Patel B; Cheng E; McLemore M; Arellano M; Heffner LT; Winton EF; Bodo I; Langston A; Kota V; Gaddh M
Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study
Volume: 18 Page(s): S204 - S205
09/01/2018 Authors: DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA
Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.
Bone Marrow Transplant Volume: 53 Page(s): 826 - 831
07/01/2018 Authors: Khoury HJ; Langston AA; Kota VK; Wilkinson JA; Pusic I; Jillella A; Bauer S; Kim AS; Roberts D; Al-Kadhimi Z
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med Volume: 378 Page(s): 2386 - 2398
06/21/2018 Authors: DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA
How I treat older patients with acute myeloid leukemia.
Cancer Volume: 124 Page(s): 2472 - 2483
06/15/2018 Authors: Arellano M; Carlisle JW
Safety and Efficacy of Venetoclax (VEN) in Combination With Decitabine or Azacitidine in Treatment-Naive, Elderly Patients (>= 65 Years) With Acute Myeloid Leukemia (AML)
Volume: 181 Page(s): 11 - 12
04/01/2018 Authors: Pratz K; Pollyea D; Jonas B; Pullarkat V; Wei A; Arellano M; Becker P; Frankfurt O; Thirman M; Pigneux A
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
Lancet Oncol Volume: 19 Page(s): 216 - 228
02/01/2018 Authors: DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R
Incidence and Predictors of Left Ventricular Dysfunction Among Acute Myeloid Leukemia Patients
Volume: 130
12/07/2017 Authors: Almuwaqqat Z; Gaddh M; Schlafer D; Hutcherson D; Arellano ML; Parashar S; Kota V
Outcomes of Chronic Phase Chronic Myeloid Leukemia (CP-CML) after Sequential Treatment with Tyrosine Kinase Inhibitors (TKI)
Volume: 130
12/07/2017 Authors: Kong JH; Winton EF; Heffner L; Gaddh M; Hill B; Arellano ML; El-Rassi F; Kim A; Kota V
Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib.
Clin Lymphoma Myeloma Leuk Volume: 17 Page(s): e71 - e73
12/01/2017 Authors: Kota VK; Kong JH; Arellano M; El Rassi F; Gaddh M; Heffner LT; Winton EF; Jillella AP; McLemore ML; Khoury HJ
Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation.
Hematol Rep Volume: 9 Page(s): 7083
09/26/2017 Authors: Jillella AP; Arellano ML; Heffner LT; Gaddh M; Langston AA; Khoury HJ; Mangoankar A; Kota VK
Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Cancer Volume: 123 Page(s): 2482 - 2488
07/01/2017 Authors: Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A
TREATMENT OF PRACINOSTAT AND AZACITIDINE IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): CORRELATION BETWEEN MUTATION CLEARANCE AND CLINICAL RESPONSE
Volume: 102 Page(s): 51 - 52
06/26/2017 Authors: Takahashi K; Abaza Y; Wang F; Gumbs C; Xingzhi S; Futreal A; Atallah E; Medeiros B; Khaled S; Arellano M
SAFETY AND EFFICACY OF VENETOCLAX (VEN) IN COMBINATION WITH DECITABINE OR AZACITIDINE IN TREATMENT-NAIVE, ELDERLY PATIENTS (>= 65 YEARS) WITH ACUTE MYELOID LEUKEMIA (AML)
Volume: 102 Page(s): 175 - 176
06/26/2017 Authors: Pratz K; Pollyea DA; Jonas BA; Pullarkat V; Wei A; Arellano M; Becker PS; Frankfurt O; Thirman M; Pigneux A
A PHASE 2 STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
Volume: 102 Page(s): 50 - 50
06/26/2017 Authors: Cortes JE; Smith BD; Wang ES; Merchant A; Oehler VG; Arellano M; DeAngelo DJ; Pollyea DA; Ma WW; Zeremski M
Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)
Volume: 23 Page(s): S323 - S323
03/01/2017 Authors: Khoury HJ; Kota VK; Arellano M; Bauer S; Jillella AP; Langston AA; Al-Kadhimi Z; DeFilipp Z; Kim AS; Winton E
Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin.
Oncogene Volume: 36 Page(s): 254 - 262
01/12/2017 Authors: Elf S; Lin R; Xia S; Pan Y; Shan C; Wu S; Lonial S; Gaddh M; Arellano ML; Khoury HJ
A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit
Volume: 128
12/02/2016 Authors: Manero GG; Atallah E; Khaled SK; Arellano M; Patnaik MM; Odenike O; Sayar H; Tummala M; Patel PA; Ghalie RG
Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions
Volume: 128
12/02/2016 Authors: Kong JH; Khoury HJ; Winton EF; Heffner LT; Gaddh M; Arellano M; El-Rassi F; Kim AS; Jillella A; Bodo I
Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth.
Mol Cell Volume: 64 Page(s): 859 - 874
12/01/2016 Authors: Fan J; Lin R; Xia S; Chen D; Elf SE; Liu S; Pan Y; Xu H; Qian Z; Wang M
Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
Clin Lymphoma Myeloma Leuk Volume: 16 Page(s): 466 - 471.e1
08/01/2016 Authors: DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R
DECREASING EARLY DEATHS IN ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN AN ACADEMIC CENTER IN THE US BY USING A SIMPLIFIED TREATMENT ALGORITHM AND DEDICATED APL EXPERTS
Volume: 101 Page(s): 675 - 676
06/01/2016 Authors: Jillella A; Mody M; Harpaul G; Arellano M; Khoury H; Al-Kadhimi Z; McLemore M; Winton E; Gaddh M; Heffner L
RESULTS OF A PHASE 1B STUDY OF VENETOCLAX PLUS DECITABINE OR AZACITIDINE IN UNTREATED ACUTE MYELOID LEUKEMIA PATIENTS >= 65 YEARS INELIGIBLE FOR STANDARD INDUCTION THERAPY
Volume: 101 Page(s): 44 - 44
06/01/2016 Authors: Pollyea DA; Di Nardo C; Thirman M; Letai A; Wei A; Jonas BA; Arellano M; Frattini M; Kantarjian H; Chyla B
Costs associated with induction chemotherapy in adult acute myeloid leukemia (AML) managed in a tertiary care specialized unit.
Volume: 34
05/20/2016 Authors: Gleason S; Howard DH; Liu Y; Goldstein DA; Arellano ML; Jillella AP; Gaddh M; Kota V; Winton EF; Heffner LT
Early Allogeneic Stem Cell Transplantation Appears to Improve Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi-Institutional Review
Volume: 22 Page(s): S202 - S202
03/01/2016 Authors: Hathaway AR; Peker D; Jackson BE; Kota VK; Shah BD; Zhang L; Jillella AP; Arellano M; Heffner LT; Erba HP
Clinical significance of quantitative monitoring and mutational analysis of BCR-ABL1 transcript in Philadelphia chromosome positive B lymphoblastic leukemia.
Leuk Lymphoma Volume: 57 Page(s): 364 - 369
02/01/2016 Authors: Zhang L; Ramjit RT; Hill CE; Arellano M; Khoury HJ; Mann KP
Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)
Volume: 126
12/03/2015 Authors: Garcia-Manero G; Atallah E; Khaled SK; Arellano M; Patnaik MM; Butler TA; Ashby C; Medeiros BC
Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Who Switch to Imatinib Following Optimal Response to Second Generation Tyrosine Kinase Inhibitors
Volume: 126
12/03/2015 Authors: Kota VK; Winton EF; Arellano M; Jillella A; McLemore ML; El Rassi F; Khoury HJ
Early Allogeneic Stem Cell Transplantation and Use of Asparaginase during Induction Chemotherapy Appear to Improve Otherwise Poor Outcomes in Adult T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi Institutional Review
Volume: 126
12/03/2015 Authors: Borate U; Hathaway AR; Peker D; Jackson BE; Kota VK; Shah BD; Zhang L; Jillella A; Arellano M; Heffner LT
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience
Volume: 126
12/03/2015 Authors: Khoury HJ; Heffner LT; Arellano M; Jillella AP; Kota VK; Winton EF
ATRA Availability on Formulary for the Treatment of APL Across Hospitals in the State of Georgia
Volume: 126
12/03/2015 Authors: Wheeler S; Puttagunta H; Surati M; Panjic E; Shah A; Arellano M; Jillella A; Kota VK
Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)
Volume: 126
12/03/2015 Authors: Khoury HJ; Kota V; Arellano M; Bauer SL; Jillella AP; Langston A; Al-Kadhimi Z; DeFilipp Z; Kim AS; Winton EF
Decreasing Early Deaths in Acute Promyelocytic Leukemia (APL) By Using a Simplified Treatment Algorithm and Establishing a Network with Academic and Community Centers in USA
Volume: 126
12/03/2015 Authors: Jillella A; Arellano M; Bashey A; Vidito SI; Stuart RK; Leung C; Sitchenko K; Gaddh M; Heffner LT; Kolhe RB
Survival of Patients Diagnosed with Primary Refractory and Relapsed Acute Myeloid Leukemia from 2008-2012: A Single Institution Experience
Volume: 126
12/03/2015 Authors: Zeichner SB; Gleason S; Antun AG; Langston A; Heffner LT; Kota VK; Gaddh M; Arellano M
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Nat Cell Biol Volume: 17 Page(s): 1484 - 1496
11/01/2015 Authors: Lin R; Elf S; Shan C; Kang H-B; Ji Q; Zhou L; Hitosugi T; Zhang L; Zhang S; Seo JH
Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth
Volume: 75
08/01/2015 Authors: Jin L; Li D; Alesi G; Fan J; Kang H-B; Zhou L; Boggon T; Magliocca K; He C; Arellano M
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
Invest New Drugs Volume: 33 Page(s): 870 - 880
08/01/2015 Authors: Garcia-Manero G; Tibes R; Kadia T; Kantarjian H; Arellano M; Knight EA; Xiong H; Qin Q; Munasinghe W; Roberts-Rapp L
Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process.
Curr Treat Options Oncol Volume: 16 Page(s): 37
08/01/2015 Authors: Zeichner SB; Arellano ML
UPDATED RESULTS FROM A PHASE 2 STUDY OF PRACINOSTAT (P) IN COMBINATION WITH AZACITIDINE (AZA) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
Volume: 100 Page(s): 216 - 216
06/01/2015 Authors: Garcia-Manero G; Atallah E; Khaled S; Arellano M; Patnaik M; Esquibel V; Wood K; Medeiros B
Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link?
Cancer Volume: 121 Page(s): 872 - 875
03/15/2015 Authors: El Rassi F; Bergsagel JD; Arellano M; Gaddh M; Jillella A; Kota V; Heffner LT; Winton EF; Khoury HJ
Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth.
Cancer Cell Volume: 27 Page(s): 257 - 270
02/09/2015 Authors: Jin L; Li D; Alesi GN; Fan J; Kang H-B; Lu Z; Boggon TJ; Jin P; Yi H; Wright ER
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome.
Leuk Lymphoma Volume: 56 Page(s): 395 - 400
02/01/2015 Authors: Roboz GJ; Khoury HJ; Jabbour E; Session W; Ritchie EK; Miao H; Faderl S; Zheng W; Feldman EJ; Arellano M
A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia.
Clin Lymphoma Myeloma Leuk Volume: 14 Page(s): 534 - 539
12/01/2014 Authors: Arellano ML; Borthakur G; Berger M; Luer J; Raza A
Tyr-301 phosphorylation inhibits pyruvate dehydrogenase by blocking substrate binding and promotes the Warburg effect.
J Biol Chem Volume: 289 Page(s): 26533 - 26541
09/19/2014 Authors: Fan J; Kang H-B; Shan C; Elf S; Lin R; Xie J; Gu T-L; Aguiar M; Lonning S; Chung T-W
Early Blast Phase Transformation In Chronic Phase Chronic Myeloid Leukemia: Is Flow Cytometry The Missing Link?
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 14 Page(s): S136 - S137
09/01/2014 Authors: El Rassi F; Arellano M; Winton E; Heffner L; Gaddh M; Khoury HJ
Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth.
Mol Cell Volume: 55 Page(s): 552 - 565
08/21/2014 Authors: Shan C; Elf S; Ji Q; Kang H-B; Zhou L; Hitosugi T; Jin L; Lin R; Zhang L; Seo JH
Tyr-94 phosphorylation inhibits pyruvate dehydrogenase phosphatase 1 and promotes tumor growth.
J Biol Chem Volume: 289 Page(s): 21413 - 21422
08/01/2014 Authors: Shan C; Kang H-B; Elf S; Xie J; Gu T-L; Aguiar M; Lonning S; Hitosugi T; Chung T-W; Arellano M
Incidence and geographic distribution of adult acute leukemia in the state of Georgia.
South Med J Volume: 107 Page(s): 497 - 500
08/01/2014 Authors: El Rassi F; Ward KC; Flowers CR; Heffner LT; Waller EK; Winton EF; Vaughn J; Hill BG; Langston A; Nooka A
CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells.
Integr Biol (Camb) Volume: 6 Page(s): 766 - 780
08/01/2014 Authors: Myers DE; Yiv S; Qazi S; Ma H; Cely I; Shahidzadeh A; Arellano M; Finestone E; Gaynon PS; Termuhlen A
Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma.
Leuk Lymphoma Volume: 55 Page(s): 1498 - 1500
07/01/2014 Authors: Mitri Z; Siddiqui MT; El Rassi F; Holden JT; Heffner LT; Langston A; Waller EK; Winton E; McLemore M; Bernal-Mizrachi L
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.
J Clin Oncol Volume: 32 Page(s): 1919 - 1926
06/20/2014 Authors: Roboz GJ; Rosenblat T; Arellano M; Gobbi M; Altman JK; Montesinos P; O'Connell C; Solomon SR; Pigneux A; Vey N
A SIMPLE AND EFFECTIVE STRATEGY TO DECREASE EARLY DEATHS IN ACUTE PROMYELOCYTIC LEUKEMIA USING A STREAMLINED SET OF GUIDELINES PAIRED WITH EXPERT SUPPORT
Volume: 99 Page(s): 298 - 298
06/01/2014 Authors: Jillella A; Lane B; Rosshandler Y; Khoury JH; Arellano M; Natrajan K; Kolhe R; Bradley KT; Bashey A; Stuart R
Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.
Leukemia Volume: 28 Page(s): 658 - 665
03/01/2014 Authors: Bachanova V; Marks DI; Zhang M-J; Wang H; de Lima M; Aljurf MD; Arellano M; Artz AS; Bacher U; Cahn J-Y
Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex.
Mol Cell Volume: 53 Page(s): 534 - 548
02/20/2014 Authors: Fan J; Shan C; Kang H-B; Elf S; Xie J; Tucker M; Gu T-L; Aguiar M; Lonning S; Chen H
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
Clin Lymphoma Myeloma Leuk Volume: 13 Page(s): 657 - 663
12/01/2013 Authors: Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT
Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies.
Cancer Volume: 119 Page(s): 3784 - 3787
11/01/2013 Authors: Antun AG; Gleason S; Arellano M; Langston AA; McLemore ML; Gaddh M; el Rassi F; Bernal-Mizrachi L; Galipeau J; Heffner LT
Constitutive function of the Ikaros transcription factor in primary leukemia cells from pediatric newly diagnosed high-risk and relapsed B-precursor ALL patients.
PLoS One Volume: 8 Page(s): e80732
01/01/2013 Authors: Uckun FM; Ma H; Ishkhanian R; Arellano M; Shahidzadeh A; Termuhlen A; Gaynon PS; Qazi S
Tools to optimize the functionality of a leukemia clinical trial team.
Leuk Lymphoma Volume: 54 Page(s): 110 - 116
01/01/2013 Authors: Bethelmie-Bryan B; Lord K; Holloway S; Safavi F; Shepard M; Rogers S; Harvey RD; Rodger K; Waller EK; El-Rayes B
Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation.
Nat Commun Volume: 4 Page(s): 1790
01/01/2013 Authors: Hitosugi T; Zhou L; Fan J; Elf S; Zhang L; Xie J; Wang Y; Gu T-L; Alekovi M; LeRoy G
Update on optimal management of acute myeloid leukemia.
Clin Med Insights Oncol Volume: 7 Page(s): 181 - 197
01/01/2013 Authors: El Rassi F; Arellano M
Incidence and Geographic Distribution of Adult Acute Lymphoblastic Leukemia in the State of Georgia
Volume: 120
11/16/2012 Authors: El Rassi F; Arellano M; Heffner LT; Waller EK; Winton EF; Ward K; Khoury HJ
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth.
Cancer Cell Volume: 22 Page(s): 585 - 600
11/13/2012 Authors: Hitosugi T; Zhou L; Elf S; Fan J; Kang H-B; Seo JH; Shan C; Dai Q; Zhang L; Xie J
Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.
Cancer Volume: 118 Page(s): 5278 - 5282
11/01/2012 Authors: Arellano M; Pakkala S; Langston A; Tighiouart M; Pan L; Chen Z; Heffner LT; Lonial S; Winton E; Khoury HJ
Is the incidence of heparin-induced thrombocytopenia affected by the increased use of heparin for VTE prophylaxis?
Chest Volume: 142 Page(s): 1175 - 1178
11/01/2012 Authors: Zhou A; Winkler A; Emamifar A; Gartland B; Duncan A; Antun A; Arellano M; Tindol GA; Levy JH; Bornstein WA
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
Lancet Oncol Volume: 13 Page(s): 1096 - 1104
11/01/2012 Authors: Kantarjian H; Faderl S; Garcia-Manero G; Luger S; Venugopal P; Maness L; Wetzler M; Coutre S; Stock W; Claxton D
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase.
Br J Haematol Volume: 158 Page(s): 608 - 614
09/01/2012 Authors: Muringampurath-John D; Jaye DL; Flowers CR; Saxe D; Chen Z; Lechowicz MJ; Weisenburger DD; Bast M; Arellano ML; Bernal-Mizrachi L
A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.
Cancer Volume: 118 Page(s): 3556 - 3564
07/15/2012 Authors: Khoury HJ; Garcia-Manero G; Borthakur G; Kadia T; Foudray MC; Arellano M; Langston A; Bethelmie-Bryan B; Rush S; Litwiler K
A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents
Volume: 30
05/20/2012 Authors: Garcia-Manero G; Luger SM; Goldberg S; Altman JK; Arellano ML; Wetzler M; Seiter K; Chiao JH; Kantarjian H
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma.
Leuk Lymphoma Volume: 53 Page(s): 725 - 727
04/01/2012 Authors: Muringampurath-John D; Flowers CR; Toscano M; Zhengjia C; Kaufman JL; Arellano M; Bernal-Mizrachi L; Heffner LT; Lechowicz M-J; McLemore M
Managing chronic myeloid leukemia: a coordinated team care perspective.
Clin Lymphoma Myeloma Leuk Volume: 12 Page(s): 88 - 93
04/01/2012 Authors: Holloway S; Lord K; Bethelmie-Bryan B; Shepard MW; Neely J; McLemore M; Reddy SK; Montero A; Jonas WS; Gladney SP
Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia.
Leuk Lymphoma Volume: 53 Page(s): 435 - 440
03/01/2012 Authors: Claxton D; Erba HP; Faderl S; Arellano M; Lyons RM; Kovacsovics T; Gabrilove J; Huebner D; Gandhi PJ; Kantarjian H
High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years.
Cancer Volume: 118 Page(s): 428 - 433
01/15/2012 Authors: Arellano M; Winton E; Pan L; Lima L; Tighiouart M; Bhalla K; Heffner LT; Neely J; Hutcherson D; McLemore M
Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.
Leuk Lymphoma Volume: 52 Page(s): 2237 - 2253
12/01/2011 Authors: Stock W; Douer D; DeAngelo DJ; Arellano M; Advani A; Damon L; Kovacsovics T; Litzow M; Rytting M; Borthakur G
Vinorelbine, Paclitaxel, Etoposide, Cisplatin and Cytarabine (VTEPA) Is An Effective Salvage Therapy for Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) but Not for R/R Diffuse Large B Cell Lymphoma (DLBCL)
Volume: 118 Page(s): 707 - 708
11/18/2011 Authors: Sinha R; King N; Shenoy PJ; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman JL; Heffner LT
Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia.
Clin Lymphoma Myeloma Leuk Volume: 11 Page(s): 427 - 432
10/01/2011 Authors: Arellano M; Bernal-Mizrachi L; Pan L; Tighiouart M; Souza L; Guo X; McLemore M; Lima L; Sunay S; Heffner LT
Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?
Leuk Lymphoma Volume: 52 Page(s): 1010 - 1016
06/01/2011 Authors: Lima LM; Sampat K; Assouline S; Saxe D; Nault S; Tighiouart M; McLemore M; Arellano M; Winton E; Bernal-Mizrachi L
Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond.
Cancer Volume: 117 Page(s): 1245 - 1252
03/15/2011 Authors: Lima L; Bernal-Mizrachi L; Saxe D; Mann KP; Tighiouart M; Arellano M; Heffner L; McLemore M; Langston A; Winton E
Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters.
Leuk Lymphoma Volume: 51 Page(s): 1473 - 1477
08/01/2010 Authors: Tran H; Arellano M; Chamsuddin A; Flowers C; Heffner LT; Langston A; Lechowicz MJ; Tindol A; Waller E; Winton EF
Safety and efficacy of HiDAC induction in de novo AML patients age 60 and older.
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Arellano ML; Pan L; Lima L; Tighiouart M; Heffner LT; Langston AA; McLemore M; Neely J; Winton EF; Khoury HJ
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.
J Clin Oncol Volume: 28 Page(s): 549 - 555
02/01/2010 Authors: Kantarjian HM; Erba HP; Claxton D; Arellano M; Lyons RM; Kovascovics T; Gabrilove J; Craig M; Douer D; Maris M
Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia.
J Blood Med Volume: 1 Page(s): 221 - 225
01/01/2010 Authors: Lima LM; Arellano M; Holloway S; Shepard M; McMillan S; Khoury HJ
Prognostic Significance of Circulating Lymphoma Cells in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Volume: 114 Page(s): 1151 - 1152
11/20/2009 Authors: Muringampurath-John D; Flowers CR; Jabbar AA; Sinha R; Arellano M; Bernal-Mizrachi L; Kaufman JL; Jaye DL; Chen Z; Lechowicz MJ
A Phase 1 Dose-Escalation Study of the Novel KSP Inhibitor ARRY-520 in Advanced Leukemias.
Volume: 114 Page(s): 808 - 808
11/20/2009 Authors: Garcia-Manero G; Khoury HJ; Borthakur G; Ravandi F; Kadia T; Estrov Z; Jabbour E; Foudray MC; Arellano M; Langston A
Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are >= 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors
Volume: 114 Page(s): 822 - 823
11/20/2009 Authors: Erba HP; Faderl S; Claxton DF; Arellano M; Lyons RM; Kovacsovics TJ; Gabrilove J; Eckert S; Huebner D; Kantarjian HM
Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors
Volume: 114 Page(s): 814 - 814
11/20/2009 Authors: Gabrilove J; Faderl S; Erba HP; Claxton DF; Arellano M; Lyons RM; Kovacsovics TJ; Eckert S; Huebner D; Kantarjian HM
CLASSIC II: UPDATED REMISSION DURATION AND SURVIVAL RESULTS OF SINGLE AGENT CLOFARABINE IN PREVIOUSLY UNTREATED OLDER ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA AND AT LEAST ONE UNFAVORABLE BASELINE PROGNOSTIC FACTOR
Volume: 94 Page(s): 336 - 336
06/07/2009 Authors: Kantarjian M; Erba P; Claxton F; Arellano ML; Lyons RM; Kovacsovics TJ; Gabrilove J; Eckert S; Faderl S
CLASSIC II: UPDATED REMISSION DURATION AND SURVIVAL RESULTS OF SINGLE AGENT CLOFARABINE IN PREVIOUSLY UNTREATED OLDER ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA AND AT LEAST ONE UNFAVORABLE BASELINE PROGNOSTIC FACTOR
Volume: 94 Page(s): 336 - 336
06/01/2009 Authors: Kantarjian M; Erba P; Claxton F; Arellano ML; Lyons RM; Kovacsovics TJ; Gabrilove J; Eckert S; Faderl S
Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor (s)
Volume: 27
05/20/2009 Authors: Erba HP; Kantarjian HM; Claxton DF; Arellano M; Lyons RM; Kovacsovics TJ; Gabrilove J; Eckert S; Faderl S
Does pre-imatinib (IM) fluorescence in situ hybridization (FISH) predict myelosuppression and outcomes in chronic myeloid leukemia (CML)?
Volume: 27
05/20/2009 Authors: Lima L; Assouline SE; Saxe D; Mann K; McLemore M; Souza L; Arellano M; Winton EF; Bernal-Mizrachi L; Khoury HJ
Monitoring chronic myeloid leukemia (CML) response to tyrosine kinase inhibitors (TKI) and homoharringtonine (HHT) using peripheral blood (PB) fluorescence in situ hybridization (FISH) and quantitative RT-PCR (Q-PCR): Are bone marrow biopsies still needed?
Volume: 27
05/20/2009 Authors: Khoury HJ; Lima L; Saxe D; Mann KP; Arellano M; Heffner L; Bernal-Mizrachi L; McLemore M; Langston A; Winton E
Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML)
Volume: 27
05/20/2009 Authors: Arellano ML; Winton E; Pan L; Souza L; Sunay S; Lima L; McLemore M; Heffner LT; Langston A; Khoury HJ
Does pre-imatinib (IM) fluorescence in situ hybridization (FISH) predict myelosuppression and outcomes in chronic myeloid leukemia (CML)?
J Clin Oncol Volume: 27 Page(s): 7071
05/20/2009 Authors: Lima L; Assouline SE; Saxe D; Mann K; McLemore M; Souza L; Arellano M; Winton EF; Bernal-Mizrachi L; Khoury HJ
Monitoring chronic myeloid leukemia (CML) response to tyrosine kinase inhibitors (TKI) and homoharringtonine (HHT) using peripheral blood (PB) fluorescence in situ hybridization (FISH) and quantitative RT-PCR (Q-PCR): Are bone marrow biopsies still needed?
J Clin Oncol Volume: 27 Page(s): 7064
05/20/2009 Authors: Khoury HJ; Lima L; Saxe D; Mann KP; Arellano M; Heffner L; Bernal-Mizrachi L; McLemore M; Langston A; Winton E
Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML).
J Clin Oncol Volume: 27 Page(s): 7070
05/20/2009 Authors: Arellano ML; Winton E; Pan L; Souza L; Sunay S; Lima L; McLemore M; Heffner LT; Langston A; Khoury HJ
Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s).
J Clin Oncol Volume: 27 Page(s): 7062
05/20/2009 Authors: Erba HP; Kantarjian HM; Claxton DF; Arellano M; Lyons RM; Kovacsovics TJ; Gabrilove J; Eckert S; Faderl S
Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy
Volume: 112 Page(s): 209 - 209
11/16/2008 Authors: Erba HP; Kantarjian H; Claxton DF; Arellano M; Lyons RM; Kovacsovics TJ; Gabrilove J; Eckert S; Abichandani R; Faderl S
Regulation of alloimmune responses by dendritic cell subsets.
Exp Hematol Volume: 36 Page(s): 1309 - 1317
10/01/2008 Authors: Lonial S; Torre C; David E; Harris W; Arellano M; Waller EK
Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma.
Bone Marrow Transplant Volume: 42 Page(s): 529 - 534
10/01/2008 Authors: Murali S; Winton E; Waller EK; Heffner LT; Lonial S; Flowers C; Kaufman J; Arellano M; Lechowicz MJ; Mann KP
PHASE II STUDY OF SINGLE AGENT CLOFARABINE IN PREVIOUSLY UNTREATED OLDER ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) UNLIKELY TO BENEFIT FROM STANDARD INDUCTION CHEMOTHERAPY
Volume: 93 Page(s): 354 - 354
06/27/2008 Authors: Erba H; Kantarjian H; Claxton D; Arellano M; Lyons R; Kovacsovics T; Gabrilove J; Eckert S; Abichandani R; Faderl S
PHASE II STUDY OF SINGLE AGENT CLOFARABINE IN PREVIOUSLY UNTREATED OLDER ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) UNLIKELY TO BENEFIT FROM STANDARD INDUCTION CHEMOTHERAPY
Volume: 93 Page(s): 354 - 354
06/01/2008 Authors: Erba H; Kantarjian H; Claxton D; Arellano M; Lyons R; Kovacsovics T; Gabrilove J; Eckert S; Abichandani R; Faderl S
Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy
JOURNAL OF CLINICAL ONCOLOGY Volume: 26
05/20/2008 Authors: Erba HP; Kantarjian HM; Claxton D; Arellano M; Lyons R; Kovacsovics T; Gabrilove J; Eckert S; Abichandani R; Faderl S
Induction of GvL after allogeneic stem cell transplantation
JOURNAL OF CLINICAL ONCOLOGY Volume: 26
05/20/2008 Authors: Arellano ML; Harris W; Langston A; McMillan S; Rosenthal H; Waller EK
Patulin, a mycotoxin, has potent cytotoxic activity on actue lymphoblastic leukemia and induce apoptosis through intrinsic and extrinsic pathways
Volume: 110 Page(s): 151B - 152B
11/16/2007 Authors: Wang F; David E; Lonial S; Arellano M; Khoury HJ; Langston A; Lechowicz MJ; Waller N
Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation.
Biol Blood Marrow Transplant Volume: 13 Page(s): 895 - 904
08/01/2007 Authors: Ninan MJ; Flowers CR; Roback JD; Arellano ML; Waller EK
The occurrence of idiopathic secondary post-transplant thrombocytopenia and the kinetics of platelet recovery predict survival in patients undergoing autologous hematopoietic progenitor cell transplantation
Volume: 25
06/20/2007 Authors: Waller E; Ninan MJ; Roback J; Arellano M; Flowers C
Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
Biol Blood Marrow Transplant Volume: 13 Page(s): 116 - 123
01/01/2007 Authors: Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
Deep venous thromboses associated with peripherally inserted central catheters in patients with hematological malignancies.
Volume: 108 Page(s): 226B - 226B
11/16/2006 Authors: Tran H; Chamsuddin A; Winton EF; Heffner L; Langston A; Waller N; Arellano M; Khoury HJ
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
Leuk Lymphoma Volume: 47 Page(s): 2155 - 2162
10/01/2006 Authors: Lonial S; Arellano M; Hutcherson D; Langston A; Flowers C; Heffner LT; Winton E; Jo Lechowicz M; Waller EK
Idiopathic secondary post-transplant thrombocytopenia (ISPT) following autologous hematopoietic progenitor cell transplantation (HPCT) is associated with transplantation of lower numbers of primitive hematopoietic progenitors
Volume: 12 Page(s): 132 - 132
02/01/2006 Authors: Ninan MJ; Arellano M; Philip A; Langston A; Flowers CR; Lonial S; Kaufman J; Lechowicz M; Khoury JH; Roback J
Reduced-intensity conditioning permits a significant graft vs leukemia (GvL) effect for acute leukemia
Volume: 12 Page(s): 69 - 70
02/01/2006 Authors: Arellano M; Flowers C; Waller E; Lonial S; Kaufman J; Winton E; Khoury H; Langston A
Decreased incidence of relapse in patients with acute leukemia transplanted from matched unrelated donors: Induction of GvL
Volume: 106 Page(s): 570A - 571A
11/16/2005 Authors: Arellano ML; Langston A; Lonial S; Flowers C; Khoury JH; Winton E; Waller EK; Mary LJ
Dendritic cell-directed cytokines induced a GvL effect in patients with acute leukemia who relapsed after allogeneic transplant
Volume: 33 Page(s): 86 - 86
07/01/2005 Authors: Waller EK; Arellano M
Results of a clinical phase I dose-escalation study of cylarabine in combination with fixed dose vinorelbine, paclitaxel, etoposide, and cisplatin (VTEPA) for the treatment of relapsed/refractory lymphoma.
Volume: 23 Page(s): 607S - 607S
06/01/2005 Authors: Arellano ML; Lonial S; Langston A; Flowers C; Heffner T; Hutcherson D; Winton E; Waller E
Predictors of more rapid lymphoid reconstitution after allogeneic transplantation
Volume: 104 Page(s): 864A - 864A
11/16/2004 Authors: Arellano ML; Moore SG; Kudchadkar R; Flowers CR; Langston AA; Lonial S; Lechowicz MJ; Waller EK
Granulocyte-macrophage-colony-stimulating factor and other cytokines: as adjuncts to cancer immunotherapy, stem cell transplantation, and vaccines.
Curr Hematol Rep Volume: 3 Page(s): 424 - 431
11/01/2004 Authors: Arellano M; K Waller E
Mortality in a cohort of inner city patients with tuberculosis.
Volume: 46 Page(s): 13A - 13A
01/01/1998 Authors: Arellano M; Sotir M; Palmer B; Griner F; Bock N; Blumberg HM

Directory section navigation

Profile